Free Trial

Cantor Fitzgerald Reaffirms Overweight Rating for DocGo (NASDAQ:DCGO)

DocGo logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Cantor Fitzgerald reaffirmed its Overweight rating on DocGo, even as other analysts remain mixed on the stock.
  • Recent analyst actions include price-target cuts from Canaccord Genuity and Stifel, while Needham reiterated a Buy rating; the stock currently has a consensus rating of Hold with a $2.38 target price.
  • DocGo shares were up 2.6% on Monday to $0.59, near their 12-month low of $0.49, with a market cap of about $57.8 million.
  • MarketBeat previews the top five stocks to own by June 1st.

DocGo (NASDAQ:DCGO - Get Free Report)'s stock had its "overweight" rating restated by equities research analysts at Cantor Fitzgerald in a research report issued on Monday,Benzinga reports.

Several other research firms have also recently weighed in on DCGO. Canaccord Genuity Group dropped their price target on shares of DocGo from $1.50 to $1.00 and set a "hold" rating for the company in a research note on Wednesday, March 25th. Needham & Company LLC reissued a "buy" rating and set a $3.00 target price on shares of DocGo in a research note on Tuesday, March 17th. Finally, Stifel Nicolaus decreased their price target on DocGo from $4.00 to $2.50 and set a "buy" rating on the stock in a research note on Tuesday, March 17th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $2.38.

Get Our Latest Research Report on DCGO

DocGo Trading Up 2.6%

DocGo stock opened at $0.59 on Monday. The company has a 50-day moving average price of $0.65 and a 200 day moving average price of $0.83. DocGo has a 12-month low of $0.49 and a 12-month high of $1.78. The stock has a market cap of $57.77 million, a P/E ratio of -0.31 and a beta of 1.02.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Neuberger Berman Group LLC acquired a new stake in DocGo during the 4th quarter worth approximately $29,000. Cerity Partners LLC acquired a new position in shares of DocGo in the second quarter worth $37,000. Public Employees Retirement System of Ohio purchased a new stake in shares of DocGo during the fourth quarter worth $40,000. Engineers Gate Manager LP purchased a new stake in shares of DocGo during the second quarter worth $52,000. Finally, Royce & Associates LP acquired a new stake in shares of DocGo in the third quarter valued at $64,000. Hedge funds and other institutional investors own 56.44% of the company's stock.

DocGo Company Profile

(Get Free Report)

DocGo, Inc is a U.S.-based integrated healthcare company that delivers on-demand and mobile healthcare services. The company’s business model centers on deploying customized medical clinics paired with a digital care platform to bring primary and acute care directly to patients. Through a combination of telemedicine and over-the-road medical units, DocGo addresses routine medical exams, chronic disease management, occupational health screenings, specialist consultations and urgent care interventions.

In addition to its mobile clinic fleet, DocGo’s digital platform offers 24/7 virtual care, facilitating remote consultations via video, phone or secure messaging.

Further Reading

Analyst Recommendations for DocGo (NASDAQ:DCGO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in DocGo Right Now?

Before you consider DocGo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DocGo wasn't on the list.

While DocGo currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines